Trial Profile
An Open Label Phase 1 Study of ADVM-022 (AAV.7m8-aflibercept) in Neovascular (Wet) Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Ixoberogene soroparvovec (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms OPTIC
- Sponsors Adverum Biotechnologies
- 26 Sep 2023 According to an Adverum Biotechnologies media release, Presentation of OPTIC four-year Ixo-vec aflibercept protein expression data and three-year extension efficacy and safety data at the American Academy Ophthalmology (AAO) Meeting in November 2023.
- 10 Aug 2023 According to an Adverum Biotechnologies media release, combined OPTIC and LUNA trials will follow approximately 90 wet AMD subjects dosed with Ixo-vec out to five years to inform global pivotal trials
- 04 Aug 2023 Status changed from active, no longer recruiting to completed.